Mortality estimates by age and sex among persons living with HIV after ART initiation in Zambia using electronic medical records supplemented with tracing a sample of lost patients: A cohort study


Autoři: Andrew D. Kerkhoff aff001;  Kombatende Sikombe aff002;  Ingrid Eshun-Wilson aff003;  Izukanji Sikazwe aff002;  David V. Glidden aff001;  Jake M. Pry aff002;  Paul Somwe aff002;  Laura K. Beres aff005;  Sandra Simbeza aff002;  Chanda Mwamba aff002;  Chama Bukankala aff002;  Cardinal Hantuba aff002;  Carolyn Bolton Moore aff002;  Charles B. Holmes aff004;  Nancy Padian aff008;  Elvin H. Geng aff003
Působiště autorů: Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, San Francisco, California, United States of America aff001;  Centre for Infectious Disease Research in Zambia, Lusaka, Zambia aff002;  Division of Infectious Diseases, Department of Medicine, Washington University, St. Louis, Missouri, United States of America aff003;  Center for Dissemination and Implementation, Institute for Public Health, Washington University, St. Louis, Missouri, United States of America aff004;  Johns Hopkins University, Baltimore, Maryland, United States of America aff005;  University of Alabama at Birmingham, Birmingham, Alabama, United States of America aff006;  Georgetown University, Washington, District of Columbia, United States of America aff007;  University of California, Berkeley, Berkeley, California, United States of America aff008
Vyšlo v časopise: Mortality estimates by age and sex among persons living with HIV after ART initiation in Zambia using electronic medical records supplemented with tracing a sample of lost patients: A cohort study. PLoS Med 17(5): e32767. doi:10.1371/journal.pmed.1003107
Kategorie: Research Article
doi: 10.1371/journal.pmed.1003107

Souhrn

Background

Men in sub-Saharan Africa have lower engagement and retention in HIV services compared to women, which may result in differential survival. However, the true magnitude of difference in HIV-related mortality between men and women receiving antiretroviral therapy (ART) is incompletely characterized.

Methods and findings

We evaluated HIV-positive adults ≥18 years old newly initiating ART in 4 Zambian provinces (Eastern, Lusaka, Southern, and Western). In addition to mortality data obtained from routine electronic medical records, we intensively traced a random sample of patients lost to follow-up (LTFU) and incorporated tracing outcomes through inverse probability weights. Sex-specific mortality rates and rate differences were determined using Poisson regression. Parametric g-computation was used to estimate adjusted mortality rates by sex and age. The study included 49,129 adults newly initiated on ART between August 2013 and July 2015; overall, the median age among patients was 35 years, the median baseline CD4 count was 262 cells/μl, and 37.2% were men. Men comprised a smaller proportion of individuals starting ART (37.2% versus 62.8%), tended to be older (median age 37 versus 33 years), and tended to have lower CD4 counts (median 220 versus 289 cells/μl) at the time of ART initiation compared to women. The overall rate of mortality among men was 10.3 (95% CI 8.2–12.4) deaths/100 person-years (PYs), compared to 5.5 (95% CI 4.3–6.8) deaths/100 PYs among women (difference +4.7 [95% CI 2.3–7.2] deaths/100 PYs; p < 0.001). Compared to women in the same age groups, men’s mortality rates were particularly elevated among those <30 years old (+6.7 deaths/100 PYs difference), those attending rural health centers (+9.4 deaths/100 PYs difference), those who had an initial CD4 count < 100 cells/μl (+9.2 deaths/100 PYs difference), and those who were unmarried (+8.0 deaths/100 PYs difference). After adjustment for potential confounders and mediators including CD4 count, a substantially higher mortality rate was predicted among men <30 years old compared to women of the same age, while women ≥50 years old had a mortality rate similar to that of age-matched men, but considerably higher than that predicted among young women (<30 years old). No clinically significant differences were evident with respect to rates of facility transfer or care disengagement between men and women. The main study limitations were the inability to successfully ascertain outcomes in all patients selected for tracing and missing clinical and laboratory data due to the use of medical records.

Conclusions

In this study, we found that among HIV-positive adults newly initiating ART, mortality among men exceeded mortality among women; disparities were most pronounced among young patients. Older women, however, also experienced high mortality. Specific interventions for men and older women at highest mortality risk are needed to improve HIV treatment outcomes.

Klíčová slova:

Adults – Africa – Antiretroviral therapy – Death rates – HIV – HIV diagnosis and management – Tuberculosis – Zambia


Zdroje

1. Sharma M, Barnabas RV, Celum C. Community-based strategies to strengthen men’s engagement in the HIV care cascade in sub-Saharan Africa. PLoS Med. 2017;14:e1002262. doi: 10.1371/journal.pmed.1002262 28399122

2. Joint United Nations Programme on HIV/AIDS. Addressing a blind spot in the response to HIV—reaching out to men and boys. Geneva: Joint United Nations Programme on HIV/AIDS; 2017.

3. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, Lawn SD, et al. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr. 2010;55:e17–23. doi: 10.1097/QAI.0b013e3181f275fd 20827216

4. Tsai AC, Siedner MJ. The missing men: HIV treatment scale-up and life expectancy in sub-Saharan Africa. PLoS Med. 2015;12:e1001906. doi: 10.1371/journal.pmed.1001906 26599825

5. Auld AF, Shiraishi RW, Mbofana F, Couto A, Fetogang EB, El-Halabi S, et al. Lower levels of antiretroviral therapy enrollment among men with HIV compared with women—12 countries, 2002–2013. MMWR Morb Mortal Wkly Rep. 2015;64:1281–6. doi: 10.15585/mmwr.mm6446a2 26605861

6. Mills EJ, Beyrer C, Birungi J, Dybul MR. Engaging men in prevention and care for HIV/AIDS in Africa. PLoS Med. 2012;9:e1001167. doi: 10.1371/journal.pmed.1001167 22346735

7. Shand T, de Boor HT, van den Berg W, Peacock D, Pascoe L. The HIV blind spot: men and HIV testing, treatment and care in sub‐Saharan Africa. IDS Bull. 2014;45:53–60. doi: 10.1111/1759-5436.12068

8. Colvin CJ. Strategies for engaging men in HIV services. Lancet HIV. 2019;6:E191–200. doi: 10.1016/S2352-3018(19)30032-3 30777726

9. Skovdal M, Campbell C, Madanhire C, Mupambireyi Z, Nyamukapa C, Gregson S. Masculinity as a barrier to men’s use of HIV services in Zimbabwe. Global Health. 2011;7:13. doi: 10.1186/1744-8603-7-13 21575149

10. Chikovore J, Hart G, Kumwenda M, Chipungu G, Desmond N, Corbett EL. TB and HIV stigma compounded by threatened masculinity: implications for TB health-care seeking in Malawi. Int J Tuberc Lung Dis. 2017;21:26–33. doi: 10.5588/ijtld.16.0925 29025482

11. Jewkes R, Morrell R. Gender and sexuality: emerging perspectives from the heterosexual epidemic in South Africa and implications for HIV risk and prevention. J Int AIDS Soc. 2010;13:6. doi: 10.1186/1758-2652-13-6 20181124

12. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2016.

13. Psaros C, Remmert JE, Bangsberg DR, Safren SA, Smit JA. Adherence to hiv care after pregnancy among women in sub-Saharan Africa: falling off the cliff of the treatment cascade. Curr HIV/AIDS Rep. 2015;12:1–5. doi: 10.1007/s11904-014-0252-6 25620530

14. Leichliter JS, Paz-Bailey G, Friedman AL, Habel MA, Vezi A, Sello M, et al. “Clinics aren’t meant for men”: sexual health care access and seeking behaviours among men in Gauteng province, South Africa. SAHARA J. 2011;8:82–8. doi: 10.1080/17290376.2011.9724989 23237685

15. Fleming PJ, Colvin C, Peacock D, Dworkin SL. What role can gender-transformative programming for men play in increasing men’s HIV testing and engagement in HIV care and treatment in South Africa? Cult Health Sex. 2016;18:1251–64. doi: 10.1080/13691058.2016.1183045 27267890

16. Tsai AC, Bangsberg DR, Weiser SD. Harnessing poverty alleviation to reduce the stigma of HIV in sub-Saharan Africa. PLoS Med. 2013;10:e1001557. doi: 10.1371/journal.pmed.1001557 24319400

17. Camlin CS, Ssemmondo E, Chamie G, Ayadi El AM, Kwarisiima D, Sang N, et al. Men “missing” from population-based HIV testing: insights from qualitative research. AIDS Care. 2016;28:67–73. doi: 10.1080/09540121.2016.1164806 27421053

18. Bor J, Chimbindi N, Haber N, Herbst K, Mutevedzi T, Tanser F, et al. Mass HIV treatment and sex disparities in life expectancy: demographic surveillance in rural South Africa. PLoS Med. 2015;12:e1001905. doi: 10.1371/journal.pmed.1001905 26599699

19. Johnson LF, May MT, Dorrington RE, Cornell M, Boulle A, Egger M, et al. Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: a mathematical modelling study. PLoS Med. 2017;14:e1002468. doi: 10.1371/journal.pmed.1002468 29232366

20. Cornell M, Johnson LF, Wood R, Tanser F, Fox MP, Prozesky H, et al. Twelve-year mortality in adults initiating antiretroviral therapy in South Africa. J Int AIDS Soc. 2017;20:21902. doi: 10.7448/IAS.20.1.21902 28953328

21. Naidoo K, Hassan-Moosa R, Yende-Zuma N, Govender D, Padayatchi N, Dawood H, et al. High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa. PLoS ONE. 2017;12:e0184124. doi: 10.1371/journal.pone.0184124 28902869

22. Holmes CB, Sikazwe I, Sikombe K, Eshun-Wilson I, Czaicki N, Beres LK, et al. Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: findings from a multistage sampling-based survey. PLoS Med. 2018;15:e1002489. doi: 10.1371/journal.pmed.1002489 29329301

23. Beckham SW, Beyrer C, Luckow P, Doherty M, Negussie EK, Baral SD. Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19:21106. doi: 10.7448/IAS.19.1.21106 27834182

24. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med. 2012;9:e1001304. doi: 10.1371/journal.pmed.1001304 22973181

25. Hawkes S, Buse K. Gender and global health: evidence, policy, and inconvenient truths. Lancet. 2013;381:1783–7. doi: 10.1016/S0140-6736(13)60253-6 23683645

26. Dovel K, Yeatman S, Watkins S, Poulin M. Men’s heightened risk of AIDS-related death: the legacy of gendered HIV testing and treatment strategies. AIDS. 2015;29(10):1123–5. doi: 10.1097/QAD.0000000000000655 26035315

27. Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.

28. Porter K, Gourlay A. Men and the young are key to reaching the first 90. Lancet HIV. 2017;4:e479–80. doi: 10.1016/S2352-3018(17)30127-3 28779854

29. Sikazwe I, Eshun-Wilson I, Sikombe K, Czaicki N, Somwe P, Mody A, et al. Retention and viral suppression in a cohort of HIV patients on antiretroviral therapy in Zambia: regionally representative estimates using a multistage-sampling-based approach. PLoS Med. 2019;16:e1002811. doi: 10.1371/journal.pmed.1002811 31150380

30. Elm von E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7. doi: 10.1016/S0140-6736(07)61602-X 18064739

31. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300:506–7. doi: 10.1001/jama.300.5.506 18677022

32. Geng EH, Glidden DV, Bwana MB, Musinguzi N, Emenyonu N, Muyindike W, et al. Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS ONE. 2011;6:e21797. doi: 10.1371/journal.pone.0021797 21818265

33. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012;26:2059–67. doi: 10.1097/QAD.0b013e3283578b9b 22781227

34. Dawood H, Hassan-Moosa R, Zuma N-Y, Naidoo K. Mortality and treatment response amongst HIV-infected patients 50 years and older accessing antiretroviral services in South Africa. BMC Infect Dis. 2018;18:168. doi: 10.1186/s12879-018-3083-z 29636023

35. Snowden JM, Rose S, Mortimer KM. Implementation of g-computation on a simulated data set: demonstration of a causal inference technique. Am J Epidemiol. 2011;173:731–8. doi: 10.1093/aje/kwq472 21415029

36. Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat. 1978;5:141–50.

37. Allison PD. Missing data. Thousand Oaks (CA): SAGE Publications; 2002.

38. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22:278–95. doi: 10.1177/0962280210395740 21220355

39. Mugisha V, Teasdale CA, Wang C, Lahuerta M, Nuwagaba-Biribonwoha H, Tayebwa E, et al. Determinants of mortality and loss to follow-up among adults enrolled in HIV care services in Rwanda. PLoS ONE. 2014;9:e85774. doi: 10.1371/journal.pone.0085774 24454931

40. Gupta A, Nadkarni G, Yang W-T, Chandrasekhar A, Gupte N, Bisson GP, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS ONE. 2011;6:e28691. doi: 10.1371/journal.pone.0028691 22220193

41. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–88. doi: 10.1016/S0140-6736(18)32203-7 30496103

42. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1859–922. doi: 10.1016/S0140-6736(18)32335-3 30415748

43. Takarinda KC, Harries AD, Shiraishi RW, Mutasa-Apollo T, Abdul-Quader A, Mugurungi O. Gender-related differences in outcomes and attrition on antiretroviral treatment among an HIV-infected patient cohort in Zimbabwe: 2007–2010. Int J Infect Dis. 2015;30:98–105. doi: 10.1016/j.ijid.2014.11.009 25462184

44. Chammartin F, Zürcher K, Keiser O, Weigel R, Chu K, Kiragga AN, et al. Outcomes of patients lost to follow-up in African antiretroviral therapy programs: individual patient data meta-analysis. Clin Infect Dis. 2018;67:1643–52. doi: 10.1093/cid/ciy347 29889240

45. Zanolini A, Sikombe K, Sikazwe I, Eshun-Wilson I, Somwe P, Bolton-Moore C, et al. Understanding preferences for HIV care and treatment in Zambia: evidence from a discrete choice experiment among patients who have been lost to follow-up. PLoS Med. 2018;15:e1002636. doi: 10.1371/journal.pmed.1002636 30102693

46. Mwamba C, Sharma A, Mukamba N, Beres L, Geng E, Holmes CB, et al. “They care rudely!”: resourcing and relational health system factors that influence retention in care for people living with HIV in Zambia. BMJ Glob Health. 2018;3:e001007. doi: 10.1136/bmjgh-2018-001007 30483408

47. Eshun-Wilson I, Mukumbwa-Mwenechanya M, Kim H-Y, Zannolini A, Mwamba CP, Dowdy D, et al. Differentiated care preferences of stable patients on antiretroviral therapy in Zambia: a discrete choice experiment. J Acquir Immune Defic Syndr. 2019;81:540–6. doi: 10.1097/QAI.0000000000002070 31021988

48. d’Elbée M, Indravudh PP, Mwenge L, Kumwenda MM, Simwinga M, Choko AT, et al. Preferences for linkage to HIV care services following a reactive self-test. AIDS. 2018;32:2043–9.

49. Zanoni BC, Archary M, Buchan S, Katz IT, Haberer JE. Systematic review and meta-analysis of the adolescent HIV continuum of care in South Africa: the cresting wave. BMJ Glob Health. 2016;1:e000004. doi: 10.1136/bmjgh-2015-000004 28588949

50. Enane LA, Vreeman RC, Foster C. Retention and adherence: global challenges for the long-term care of adolescents and young adults living with HIV. Curr Opin HIV AIDS. 2018;13:212–9. doi: 10.1097/COH.0000000000000459 29570471

51. Choko AT, Corbett EL, Stallard N, Maheswaran H, Lepine A, Johnson CC, et al. HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: an adaptive multi-arm, multi-stage cluster randomised trial. PLoS Med. 2019;16:e1002719. doi: 10.1371/journal.pmed.1002719 30601823

52. PEPFAR Solutions. Addressing the blind spot in achieving epidemic control in Malawi: implementing “male-friendly” HIV services to increase access and uptake. Washington (DC): PEPFAR Solutions; 2018 [cited 2019 Sep 30]. https://www.pepfarsolutions.org/solutions/2018/12/19/addressing-the-blind-spot-in-achieving-epidemic-control-in-malawi-implementing-male-friendly-hiv-services-to-increase-access-and-uptake.

53. PEPFAR Solutions. Male-friendly clinics in Lesotho: demand creation targeting HIV-infected men to access comprehensive health services. Washington (DC): PEPFAR Solutions; 2018 [cited 2019 Sep 30]. https://www.pepfarsolutions.org/solutions/2018/11/6/male-friendly-clinics-demand-creation-targeting-hiv-infected-men-to-access-comprehensive-health-services.

54. Grimsrud A, Barnabas RV, Ehrenkranz P, Ford N. Evidence for scale up: the differentiated care research agenda. J Int AIDS Soc. 2017;20:22024. doi: 10.7448/IAS.20.5.22024 28770588

55. Rebeiro PF, Bakoyannis G, Musick BS, Braithwaite RS, Wools-Kaloustian KK, Nyandiko W, et al. Observational study of the effect of patient outreach on return to care: the earlier the better. J Acquir Immune Defic Syndr. 2017;76:141–8. doi: 10.1097/QAI.0000000000001474 28604501

56. Nakiwogga-Muwanga A, Musaazi J, Katabira E, Alamo-Talisuna S, Colebunders R. Early tracking after a missed return visit reduces the proportion of untraceable patients at a large HIV clinic in Kampala, Uganda. J Int Assoc Provid AIDS Care. 2016;15:338–44. doi: 10.1177/2325957414530471 24718380

57. Katz IT, Kaplan R, Fitzmaurice G, Leone D, Bangsberg DR, Bekker L-G, et al. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: a retrospective cohort study. PLoS Med. 2017;14:e1002434. doi: 10.1371/journal.pmed.1002434 29136014

58. Estill J, Kerr CC, Blaser N, Salazar-Vizcaya L, Tenthani L, Wilson DP, et al. The effect of monitoring viral load and tracing patients lost to follow-up on the course of the HIV epidemic in Malawi: a mathematical model. Open Forum Infect Dis. 2018;5:493–9. doi: 10.1093/ofid/ofy092 29977952

59. Fox MP, Pascoe SJS, Huber AN, Murphy J, Phokojoe M, Gorgens M, et al. Effectiveness of interventions for unstable patients on antiretroviral therapy in South Africa: results of a cluster-randomised evaluation. Trop Med Int Health. 2018;23:1314–25. doi: 10.1111/tmi.13152 30281882

60. Bershetyn A, Odeny TA, Lyamuya R, Nakiwogga-Muwanga A, Diero L, Bwana M, et al. The causal effect of tracing by peer health workers on return to clinic among patients who were lost to follow-up from antiretroviral therapy in Eastern Africa: a “natural experiment” arising from surveillance of lost patients. Clin Infect Dis. 2017;64:1547–54. doi: 10.1093/cid/cix191 28329184

61. PEPFAR Solutions. Loss to follow-up tool: tracking and tracing HIV patients. Washington (DC): PEPFAR Solutions; 2018 [cited 2020 Apr 20]. https://www.pepfarsolutions.org/tools-2/2019/1/4/loss-to-follow-up-tool.

62. Havlir DV, Balzer LB, Charlebois ED, Clark TD, Kwarisiima D, Ayieko J, et al. HIV testing and treatment with the use of a community health approach in rural Africa. N Engl J Med. 2019;381:219–29. doi: 10.1056/NEJMoa1809866 31314966

63. Kamya MR, Petersen ML, Kwariisima D, Ayieko J, Sang N, Kabami J, et al. Search intervention reduces mortality at a population level in men with low CD4 count. Abstract number 138. Conference on Retroviruses and Opportunistic Infections; 2019 Mar 4–7; Seattle, WA, US.

64. Kranzer K, Govindasamy D, Ford N, Johnston V, Lawn SD. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2012;15:17383. doi: 10.7448/IAS.15.2.17383 23199799

65. Reniers G, Blom S, Lieber J, Herbst AJ, Calvert C, Bor J, et al. Tuberculosis mortality and the male survival deficit in rural South Africa: an observational community cohort study. PLoS ONE. 2017;12:e0185692. doi: 10.1371/journal.pone.0185692 29016619

66. World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization; 2018.

67. Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2016;13:e1002119. doi: 10.1371/journal.pmed.1002119 27598345

68. Horton KC, White RG, Houben RMGJ. Systematic neglect of men as a key population in tuberculosis. Tuberculosis (Edinb). 2018;113:249–53. doi: 10.1016/j.tube.2018.09.006 30287201

69. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24:1708–15. doi: 10.1038/s41591-018-0224-2 30397355

70. Wong NS, Chan KCW, Cheung EKH, Wong KH, Lee SS. Immune recovery of middle-aged HIV patients following antiretroviral therapy. Medicine (Baltimore). 2017;96:e7493. doi: 10.1097/MD.0000000000007493 28700495

71. Mapanga W, Girdler-Brown B, Feresu SA, Chipato T, Singh E. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review. Syst Rev. 2018;7:198. doi: 10.1186/s13643-018-0874-7 30447695

72. Kalubula M, Shen H, Makasa M, Liu L. Epidemiology of cancers in Zambia: a significant variation in cancer incidence and prevalence across the nation. BioRxiv. 2018 Aug 28. doi: 10.1101/402628

73. Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P, ART and HPV Review Group. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5:e45–58. doi: 10.1016/S2352-3018(17)30149-2 29107561

74. Cooper ES. Marriage, like income and education, fails to provide shelter for women against HIV infection in sub-Saharan Africa: widowhood and divorce increase the risk. Int Health. 2014;6:271–2. doi: 10.1093/inthealth/ihu029 24941940

75. Tenkorang EY. Marriage, widowhood, divorce and HIV risks among women in sub-Saharan Africa. Int Health. 2014;6:46–53. doi: 10.1093/inthealth/ihu003 24480991

76. Rathod SD, Timæus IM, Banda R, Thankian K, Chilengi R, Banda A, et al. Premature adult mortality in urban Zambia: a repeated population-based cross-sectional study. BMJ Open. 2016;6:e010801. doi: 10.1136/bmjopen-2015-010801 26940113

77. Roy M, Mukumbwa-Mwenechanya M, Efronson E, Sharma A, Sikazwe I, Padian N, et al. Uptake and adaptation of community adherence groups in Zambia. Abstract number 1004. Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13–16; Seattle, WA, US.

78. PEPFAR Solutions. Improving patient antiretroviral therapy retention through community adherence groups in Zambia. Washington (DC): PEPFAR Solutions; 2018 [cited 2020 Apr 20]. https://www.pepfarsolutions.org/solutions/2018/1/16/decongesting-art-clinics-in-zambia-and-improving-patients-retention-through-community-adherence-groups-mrbtk.

Štítky
Interní lékařství

Článek vyšel v časopise

PLOS Medicine


2020 Číslo 5

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Kurz originály vs. generika
nový kurz
Autoři:

Klinická farmakokinetika betablokátorů
Autoři:

Současné možnosti terapie osteoartrózy
Autoři: MUDr. Jakub Holešovský

Preferovaná úlevová léčba Asthma Bronchiale
Autoři: PharmDr. Petr Sedlák

Inhibitory karboanhydrázy v léčbě glaukomu
Autoři: MUDr. Petr Výborný, CSc., FEBO

Všechny kurzy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se